Methods

1

2

## Causal Mediation Analysis with Multiple Causally Ordered and

## **Non-ordered Mediators based on Summarized Genetic Data**

- 4 Lei Hou<sup>1,2</sup>, Yuanyuan Yu<sup>1,2</sup>, Xiaoru Sun<sup>1,2</sup>, Xinhui Liu<sup>1,2</sup>, Yifan Yu<sup>1,2</sup>, Ran Yan<sup>1,2</sup>, Hongkai
- 5 Li<sup>1,2\*†</sup>, Fuzhong Xue<sup>1,2\*†</sup>
- <sup>†</sup> Fuzhong Xue and Hongkai Li contributed equally to this work.
- 7 1. Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan,
- 8 People's Republic of China, 250000
- 9 2. Department of Epidemiology and Health Statistics, School of Public Health, Cheeloo
- 10 College of Medicine, Shandong University, Jinan, People's Republic of China, 250000
- 11 Corresponding author:
- 1. Fuzhong Xue, E-mail: xuefzh@sdu.edu.cn, Telephone: 13906405997,
- Address: School of public health, Shandong University, 44 Wenhua West Road,
- Jinan, Shandong province, China
- 2. Hongkai Li, E-mail: <u>lihongkaiyouxiang@163.com</u>, Telephone: 18310601363,
- Address: School of public health, Shandong University, 44 Wenhua West Road,
- Jinan, Shandong province, China
- 18 Short title: Causal Mediation Analysis with Multiple Mediators based on Summarized Genetic
- 19 Data
- 20 **Conflicts of Interest**
- 21 None declared

#### **Source of Funding**

22

- 23 FX was supported by the National Natural Science Foundation of China (Grant 81773547)
- 24 and Shandong Provincial Key Research and Development project (2018CXGC1210). HL was
- supported by the National Natural Science Foundation of China (Grant 82003557).

### 26 Availability of data and materials

- 27 GWAS summary data for BMI, Lipids and CVD are publicly available at
- 28 https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT\_consortium\_data\_file
- s, <a href="http://lipidgenetics.org/">http://lipidgenetics.org/</a> and <a href="http://www.cardiogramplusc4d.org/">http://lipidgenetics.org/</a> and <a href="http://www.cardiogramplusc4d.org/">http://lipidgenetics.org/</a> and <a href="http://www.cardiogramplusc4d.org/">http://www.cardiogramplusc4d.org/</a>, respectively. Code to
- 30 implement the method and reproduce all simulations and analyses is available on Github
- 31 (<a href="https://github.com/hhoulei/PSEMR">https://github.com/hhoulei/PSEMR</a>).

### 32 Ethics approval and consent to participate

- 33 Ethical approval was not sought, because this study involved analysis of publicly available
- summary-level data from GWASs, and no individual-level data were used.

#### 35 **Authors' contributions**

- 36 HL and FX conceived the study. LH, HL contributed to theoretical derivation with assistance
- 37 from YY, XL and XS. LH, RY and YY contributed to the data simulation. LH, HL and SS
- 38 contributed to the application. LH and HL wrote the manuscript with input from all other
- 39 authors. All authors reviewed and approved the final manuscript.

#### Acknowledgements

40

We would like to thank Editage (www.editage.com) for English language editing.

**Abstract** 

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

58

Causal mediation analysis aims to investigate the mechanism linking an exposure and an outcome. Dealing with the impact of unobserved confounders among the exposure, mediator and outcome has always been an issue of great concern. Moreover, when multiple mediators exist, this causal pathway intertwines with other causal pathways, making it more difficult to estimate of path-specific effects (PSEs). In this article, we propose a method (PSE-MR) to identify and estimate PSEs of an exposure on an outcome through multiple causally ordered and non-ordered mediators using Mendelian Randomization, when there are unmeasured confounders among the exposure, mediators and outcome. Additionally, PSE-MR can be used when pleiotropy exists, and can be implemented using only summarized genetic data. We also conducted simulations to evaluate the finite sample performances of our proposed estimators in different scenarios. The results show that the causal estimates of PSEs are almost unbiased with good coverage and Type I error properties. We illustrate the utility of our method through a study of exploring the mediation effects of lipids in the causal pathways from body mass index to cardiovascular disease. **Key words:** mediation analysis, multiple mediators, causally ordered mediators, causally

57

non-ordered mediators, Mendelian randomization, summarized genetic data

# **Author summary**

59

65

A new method (PSE-MR) is proposed to identify and estimate PSEs of an exposure on an outcome through multiple causally ordered and non-ordered mediators using summarized genetic data, when there are unmeasured confounders among the exposure, mediators and outcome. Lipids play important roles in the causal pathways from body mass index to cardiovascular disease

## 1 Introduction

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Mediation analyses help to uncover the mechanisms underlying causal relationships between an exposure and an outcome by using mediator variables [1]. In mediation analyses, the total effect of an exposure on an outcome is partitioned into indirect and direct effects. Indirect effects act through mediators of interest, whereas direct effects are determined by fixing the mediator at a specified level. Estimating direct and indirect effects via existing methods typically requires a stringent sequential ignorability assumption [2] that no unmeasured confounders exist among the exposure, mediators and outcome [3]. However, this assumption may not hold in practice and omitting important confounders will necessarily bias results [4]. When multiple intermediate variables  $(M_1 \text{ and } M_2)$  are involved in a study, three types of mediators with respect to  $M_1$  and  $M_2$  may arise, as shown in Figure 1. In Figure 1A,  $M_1$  is conditionally independent of  $M_2$  given the treatment (X) and measured covariates [5]. In Figure 1B,  $M_1$  and  $M_2$  are not causally ordered because they are independent of each other, conditional upon the treatment (X) and measured covariates [6]. In Figure 1C, mediators are causally ordered, and  $M_1$  is treated as a mediator-outcome confounder affected by the treatment. If we are interested in the mediator  $M_2$ , we get a two-way decomposition into an indirect effect through  $M_2$  and a direct effect (not through  $M_2$ ). Imai and Yamamoto [7] proposed an approach for all the three types of mediators under a linear structural equation model. Daniel et al. [8] considered the finest possible decomposition of the total effect when there are two causally ordered mediators, and evaluated each path-specific effect (PSE) under

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

the counterfactual framework. Additionally, VanderWeele and Vansteelandt [9] regarded the multiple mediators simultaneously as joint mediators, and defined the "joint" natural direct and indirect effects as extensions of the usual two-way decomposition of the total effect using regression-based approach and weighting approach. Several methods [10-16] have been developed to relax the sequential ignorability assumption. However, none of them allowed for the simultaneous existence of unmeasured confounders among the exposure, mediators and the outcome. Mendelian randomization (MR) analyses [17] using summarized data have recently become popular due to the increase in public availability of suitable data in large sample sizes from recently published genome-wide association studies [18]. For instance, Tikkanen E et al. (2019) performed a two-sample MR to evaluate independent causal roles of body components (fat-free mass and fat mass) on atrial fibrillation (AF) [19]. Firstly, univariate MR was used to estimate the causal effect of fat-free mass on AF by leveraging genetic variants (instrumental variables). Some genetic variants may be associated with both fat-free mass and fat mass, which is problematic because fat mass is also associated with AF. These genetic variants are invalid because they violate the assumption of exclusion restriction, since – they unlock the pathway from genetic variants to AF not via fat-free mass. This phenomenon is called horizontal pleiotropy, and fat mass is considered a pleiotropic trait [20]. In order to eliminate the effect of pleiotropy on causal estimation, multivariable MR [21] was performed to evaluate the causal role of fat-free mass on AF independent of fat mass. Similarly, we can obtain the causal effect of fat mass on AF independent of fat-free mass.

Risk factors associated with genetic variants may not always be pleiotropic traits, rather they may be mediators in the causal pathway from the exposure to the outcome (Figure 1D). In this case, these genetic variants are still valid instruments and MR can be used for mediation analysis. Burgess S et al. (2017) showed that total and direct effects in a single mediator setting can be estimated by univariate and multivariable MR analyses, respectively [22]. We will review this in Section 2.1. In Section 2.2, we extend the analysis from a single mediator setting to a multiple mediators setting (PSE-MR) for both causally ordered and non-ordered mediators. Then in Section 3, we apply our method to estimate PSEs from body mass index (BMI) to cardiovascular disease (CVD) through lipids mediators. In Section 4, we conduct simulations to compare the performance of PSE-MR in different scenarios. Finally, we discuss the methods and results of this study and its potential for application. R package **PSEMR** for implementing PSE-MR is provided in Github (https://github.com/hhoulei/PSEMR).

#### 2 Methods

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

Throughout, we let X, Y, M and G denote the exposure, outcome, mediator and genetic variant, respectively. U denotes a set of baseline covariates and potential confounders of the mediators, exposure and outcome relationships. We also let  $\theta_0$ ,  $\alpha_1$  and  $\delta_1$  denote the effect of X on Y, X on M and M on Y, respectively. The subscript j (j = 1, ..., J), denotes the j-th genetic variant. Increasingly, MR analyses are implemented using summarized data on the

associations of each genetic variant with the exposure, mediator and outcome, obtained from

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

linear regressions on non-overlapping data consortia. This included the beta-coefficients ( $\hat{\beta}_{x_i}$ ,  $\hat{\beta}_{Mj}, \hat{\beta}_{Yj}$ ) and their standard errors (se( $\hat{\beta}_{Xj}$ ), se( $\hat{\beta}_{Mj}$ ), se( $\hat{\beta}_{Yj}$ )). If the exposure X or the outcome Y is binary, then these summarized association estimates may be replaced with association estimates (log(OR)) obtained from logistic regression. Initially, we consider the indirect (through M) and direct (not through the above mediators) effects of an exposure X on an outcome Y using genetic variants G. Then we declare several assumptions. We assume all genetic variants are uncorrelated (not in linkage disequilibrium). We also assume all variables are continuous, and relationships between variables (the genetic associations with the exposure X, mediator M, and outcome Y, and the causal effects of X and M on Y as well as X on the M) are linear with homogeneity across the population. In other words, interactions between the exposure (X) and mediator (M) are not allowed unless individual data is available. We also assume that the consistency and composition assumptions in causal mediation analyses hold [24] (see S1 Appendix, Section 1). Note that we relax the assumption of no unmeasured confounders among the exposure X, mediator M, and outcome Y, which is required in most studies. 2.1 PSE-MR in one mediator setting In a single mediator setting (Figure 1D), a valid instrumental variable  $G_i$  must satisfy the following three assumptions: **Assumption** I. For each j(j=1,...,J), the instrumental variable  $G_i$  is associated with the

exposure X.

146

This assumption requires that  $G_j$  should be strongly associated with X, otherwise, weak instrumental variable bias will exist [25]. The "rule of thumb" advocates that the F statistic of each instrumental variable should be at least 10 to avoid this bias [26-27] (see S1 Appendix, Section 2.3).

- Assumption II. For each j(j=1,...,J),  $G_j \perp U$ , and these three unmeasured confounders satisfy the following criteria:
- 153 1) There is no additive X U interaction on M and Y.
- 154 2) There is no additive M-U interaction on Y.
- 155 3) There is no confounders of M-Y relationship induced by X..
- In this assumption, we posit that there is no confounders of M-Y relationship induced by X, nor any interactions between X (or M) and these confounders [17]. When the interactions between M and U exist, the direct effect of X on Y can be identified (see S1 Appendix, Section 4). Swanson S and VanderWeele T [28] suggested that the E-value can be used to examine the independence between  $G_j$  and U, that is, to evaluate the sensitivity of estimates to confounders between  $G_j$  and Y (see S1 Appendix, Section 5).
- Assumption III. For each j(j=1,...,J),  $G_i \perp Y \mid (X,U), G_i \perp M \mid (X,U)$ .
- This assumption means that there is no pleiotropy. In other words,  $G_j$  must affect Y through X, and the pathways  $G_j \to M \to Y$  or  $G_j \to Y$  (not via X) are not allowed. We examine and relax this assumption in Section 2.1.2.

## 2.1.1 PSE-MR based on IVW (PSE-IVW)

166

- For each j(j=1,...,J), we do not allow for direct effects between  $G_i$  and  $M(\gamma_{i,j}=0)$  as
- 168 well as  $G_i$  and Y (  $\gamma_{0i}=0$  ) (Figure 1D). Based on above three assumptions, the
- inverse-variance weighting method (IVW) can provide an estimate of the total effect  $\theta_T$  of
- 170 X on Y by the following weighted regression with the intercept set to zero

171 
$$\hat{\beta}_{y_j} = \theta_T \hat{\beta}_{x_j} + \varepsilon_{T_j}, \quad \varepsilon_{T_j} \sim N\left(0, se(\hat{\beta}_{y_j})^2\right). \tag{1}$$

- 172 The total effect  $\theta_T$  between X and Y can be decomposed into a direct effect
- 173  $(\theta_T = \theta_I + \theta_D = \alpha_1 \times \delta_1 + \theta_0)$  and an indirect effect via M.
- Under the framework of multivariable MR, the weighted regression model can be
- expanded by including genetic associations with the mediator

176 
$$\hat{\beta}_{y_i} = \theta_0 \hat{\beta}_{x_i} + \delta_1 \hat{\beta}_{M_i} + \varepsilon_{D_i}, \quad \varepsilon_{D_i} \sim N\left(0, se(\hat{\beta}_{y_i})^2\right)$$
 (2)

- where  $\hat{\theta}_0$  provides an estimate of the direct effect  $\theta_D$ . The indirect effect  $\theta_I$  of exposure
- on the outcome can be calculated as  $\theta_{ID} = \theta_T \theta_D$  (difference indirect effect). It is equivalent
- to  $\theta_{IP} = \alpha_1 \times \delta_1$  (product indirect effect), where  $\delta_1$  can be estimated by equation (2) and  $\alpha_1$
- can be estimated by the following weighted regression with the intercept set to zero

181 
$$\hat{\beta}_{Mj} = \alpha_1 \hat{\beta}_{Xj} + \varepsilon_{Mj}, \quad \varepsilon_{Mj} \sim N\left(0, se(\hat{\beta}_{Mj})^2\right). \tag{3}$$

- 182 The standard error of the difference and product indirect e □ ects are presented in S1 Appendix,
- Section 5. The total effect can also be estimated from individual-level data using the
- two-stage least squares (2SLS) method. The direct effect can also be estimated using 2SLS by
- regressing the outcome on fitted values of the exposure, and further on fitted values of the

186 mediator [22].

187

189

190

191

193

## 2.1.2 PSE-MR of a single mediator based on MR-Egger (PSE-Egger)

The method proposed by Burgess et al. (2017) has some limitations. This method cannot 188 be used if Assumption III is violated, that is, direct effects of  $G_j$  on M (M simultaneously plays the role of a pleiotropic trait) or  $G_i$  on Y (pleiotropic pathway) exist. Thus, we relax the Assumption III by allowing for direct effects between  $G_j$  and M ( $\gamma_{1j} \neq 0$ ) as well as  $G_j$  and  $Y(\gamma_{0j} \neq 0)$  (Figure 1D). Without the limitation of intercept set to zero, the causal 192 effect of X on Y can be obtained by MR-Egger regression. To satisfy the InSIDE assumption 194 [23] for MR-Egger, we require

$$\beta_{\chi_j} \perp \gamma_{0_j} \perp \gamma_{1_j}. \tag{4}$$

The total effect  $\theta_T$  can be estimated by the following weighted linear regression 196

197 
$$\hat{\beta}_{yj} = \gamma_T + \theta_T \hat{\beta}_{xj} + \varepsilon_{Tj}, \quad \varepsilon_{Tj} \sim N\left(0, se(\hat{\beta}_{yj})^2\right). \tag{5}$$

- $\theta_T$  can also be decomposed into the direct effect  $\theta_D = \theta_0$  and the product indirect effect  $\theta_{IP}$ , 198
- where  $\theta_D$  can be obtained by multivariable MR-Egger regression: 199

$$\hat{\beta}_{y_j} = \gamma_{0j} + \theta_0 \hat{\beta}_{x_j} + \delta_1 \hat{\beta}_{Mj} + \varepsilon_{Dj}, \quad \varepsilon_{Dj} \sim N\left(0, se(\hat{\beta}_{y_j})^2\right)$$
 (6)

- The intercept term  $\gamma_{0j}$  that differs from zero is an indicator of direct effect between  $G_j$  and 201
- Y, which is called directional pleiotropy. For product indirect effect  $\theta_{IP}$ ,  $\delta_1$  can be estimated 202
- by above equation (6), and  $\alpha_1$  can also be obtained by the following multivariable 203
- 204 MR-Egger regression:

$$\hat{\beta}_{Mi} = \gamma_{1i} + \alpha_1 \hat{\beta}_{Xi} + \varepsilon_{Mi}, \quad \varepsilon_{Mi} \sim N\left(0, se(\hat{\beta}_{Mi})^2\right)$$
 (7)

where  $\gamma_{ij}$  that differs from zero is an indicator of direct effect between  $G_i$  and M. The

estimation of standard error for difference and product indirect effect is presented in the S1

208 Appendix.

207

209

## 2.2 Extending PSE-MR to multiple mediators setting

- In this section, we extend the PSE-MR method to a multiple mediators setting. If there are n
- 211 mediators  $M_1, M_2, ..., M_n$  in the causal pathway from X to Y, PSEs can be identified. In the
- 212 multiple mediators setting, we consider two relationships among mediators: causally
- 213 non-ordered and causally ordered, respectively. In both cases, a valid instrumental variable
- 214 must satisfy Assumption | mentioned in Section 2.1, and the following Assumption || and
- 215 III\*, which extend from the Assumption II and III.
- 216 **Assumption** II\*. For each  $i, j(i=1,...,n, j=1,...,J), G_i \perp U$ .
- 1) There is no additive X U interaction on  $M_i$  and Y.
- 218 2) There is no additive  $M_i U$  interaction on Y.
- 219 3) There is no confounders of  $M_i Y$  relationship induced by X.
- 220 **Assumption**  $\text{III}^*$ . For each i, j (i = 1, ..., n, j = 1, ..., J),  $G_j \perp Y \mid (X, U), G_j \perp M_i \mid (X, U)$ .
- 221 The illustrations and examinations for Assumptions II and III can also be extended to the
- 222 multiple mediators setting.

### 223 **2.2.1 PSE-MR for causally non-ordered mediators**

- 224 Firstly, we consider causally non-ordered mediators (Figure 2A, B), where n mediators are
- independent of each other, conditional on X. Total effect  $\theta_T$  can also be estimated by

- equation (1). The direct effect  $(\theta_D = \theta_0)$  and product indirect effect  $\theta_{IP} = \sum_{i=1}^{n} \alpha_i \delta_i$  can be
- estimated by the following weighted regressions with the intercept set to zero:

228 
$$\mathbf{B} = \Psi \mathbf{A} + \boldsymbol{\varepsilon}, \ \boldsymbol{\varepsilon} \sim N(\mathbf{0}, \Sigma), \ \Sigma = diag(se(\hat{\beta}_{Y_j})^2, se(\hat{\beta}_{M_n j})^2, \cdots, se(\hat{\beta}_{M_n j})^2)$$
(8)

where 
$$B = \begin{bmatrix} \hat{\beta}_{Yj} \\ \hat{\beta}_{M_1j} \\ \hat{\beta}_{M_2j} \\ \vdots \\ \hat{\beta}_{M_nj} \end{bmatrix}, \Psi = \begin{bmatrix} \theta_0 & \delta_1 & \delta_2 & \cdots & \delta_n \\ \alpha_1 & 0 & 0 & \cdots & 0 \\ \alpha_2 & 0 & 0 & \cdots & 0 \\ \vdots & \vdots & \vdots & \cdots & \vdots \\ \alpha_n & 0 & 0 & \cdots & 0 \end{bmatrix}, A = \begin{bmatrix} \hat{\beta}_{Xj} \\ \hat{\beta}_{M_1j} \\ \hat{\beta}_{M_2j} \\ \vdots \\ \hat{\beta}_{M_nj} \end{bmatrix}, \boldsymbol{\varepsilon} = \begin{bmatrix} \boldsymbol{\varepsilon}_{0j} \\ \boldsymbol{\varepsilon}_{1j} \\ \boldsymbol{\varepsilon}_{2j} \\ \vdots \\ \boldsymbol{\varepsilon}_{nj} \end{bmatrix}.$$
 These estimations can  $\hat{\beta}_{M_nj}$ 

- also be obtained from individual-level data using 2SLS method.
- Similarly, we relax Assumption III\* by allowing for the direct effect between the
- instrumental variable  $G_j$  and mediators  $M_i$  ( $\gamma_{1j}, \gamma_{2j}, ..., \gamma_{nj}$ ), as well as  $G_j$  and Y ( $\gamma_{0j} \neq 0$ )
- 233 (Figure 2B). Under the InSIDE assumption  $\beta_{x_j} \perp \gamma_{1_j} \perp \gamma_{2_j} \perp ... \perp \gamma_{n_j} \perp \gamma_{0_j}$ , the total effect
- 234  $\theta_T$  can also be estimated by equation (5). The direct effect  $(\theta_D = \theta_0)$  and product indirect
- effect ( $\theta_{I\!\!P}$ ) can also be estimated by the following linear regression equations:

236 
$$\mathbf{B} = \boldsymbol{\gamma} + \boldsymbol{\Psi} \mathbf{A} + \boldsymbol{\varepsilon}, \ \boldsymbol{\varepsilon} \sim N(\mathbf{0}, \boldsymbol{\Sigma}), \ \boldsymbol{\Sigma} = diag(se(\hat{\boldsymbol{\beta}}_{Y_j})^2, se(\hat{\boldsymbol{\beta}}_{M_1,j})^2, \cdots, se(\hat{\boldsymbol{\beta}}_{M_n,j})^2)$$
(9)

- where  $\gamma = \begin{bmatrix} \gamma_{0j} & \gamma_{1j} & \gamma_{2j} & \cdots & \gamma_{nj} \end{bmatrix}^T$ . Intercept terms  $\gamma_{0j}$  and  $\gamma_{ij}$  (i = 1, ..., n) that differ
- 238 from zero are indicators of direct effect between  $G_j$  and Y, as well as  $G_j$  and  $M_i$ ,
- respectively. Detailed theoretical derivations are presented in S1 Appendix, section 3.

## 2.2.2 PSE-MR for causally ordered mediators

240

- When all the mediators are causally ordered (Figure 2C, D), we let  $r_{pq}$  denote the direct
- effect of  $M_p$  on  $M_q, p, q \in (1, 2, ..., n), p \neq q$ . The total effect  $\theta_T$  can also be estimated by

equation (5). The direct effect ( $\theta_D = \theta_0$ ) and product indirect effect

$$\theta_{IP} = \sum_{i=1}^{n} \alpha_{i} \delta_{i} + \sum_{i=2}^{n} \sum_{j=1}^{i-1} \alpha_{i} r_{ij} \delta_{j} + \sum_{i=3}^{n} \sum_{j=2}^{i-1} \sum_{k=1}^{j-1} \alpha_{i} r_{ij} r_{jk} \delta_{k}$$

$$+ ... + \sum_{i=n-1}^{n} \sum_{j=n-2}^{i-1} ... \sum_{h=1}^{l-1} \alpha_{i} r_{ij} ... r_{lh} \delta_{h} + \alpha_{n} r_{n(n-1)} ... r_{21} \delta_{1}$$

$$(10)$$

- can be estimated by the weighted regressions in equation (8) and (9) by substituting  $\Psi^*$  for
- $\Psi$ , where

$$\Psi^* = \begin{bmatrix}
\theta_0 & \delta_1 & \delta_2 & \cdots & \delta_n \\
\alpha_1 & 0 & 0 & \cdots & 0 \\
\alpha_2 & r_{12} & 0 & \cdots & 0 \\
\vdots & \vdots & \vdots & \cdots & \vdots \\
\alpha_n & r_{1n} & r_{2n} & \cdots & 0
\end{bmatrix}.$$

The causal effect  $r_{pq}$  from  $M_p$  to  $M_q$ ,  $p,q \in (1,2,...,n)$ ,  $p \neq q$  can be identified. Details of theoretical derivation are presented in S1 Appendix, section 3. In practice, we can use Mendelian randomization to justify the causal direction of any two mediators. Then we combine the results of causal relationships of any two mediators to obtain the ordering of

## 3 Application

multiple mediators.

We attempted to reveal the causal mechanism from body mass index (BMI) to cardiovascular disease (CVD) as an illustrative example. CVD, which includes coronary heart disease, stroke and heart failure, is the leading cause of death worldwide [29]. High BMI is an important risk factor of CVD [30]. Furthermore, dyslipidaemia in obesity is characterized by increased levels of very low density lipoprotein (VLDL) cholesterol, triacylglycerols (TG) and total cholesterol (TC), and lower high density lipoprotein (HDL) cholesterol levels levels [31].

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

Previous studies suggested that a variety of alterations in cardiac structure and function occur in the individual as adipose tissue accumulates excessively [32]. However, Van Gaal LF et al. found little evidence that LDL cholesterol is enhanced in obesity [31]. Hence, we aim to examine whether BMI affects CVD through its influence on HDL and TG. Genetic associations with BMI in 694,649 participants from European were obtained from the Genetic Investigation of ANthropometric Traits (GIANT) [33]. Genetic associations with TG and HDL in 188,577 participants were obtained from the Global Lipids Genetics Consortium (GLGC) [34]. Genetic associations with CVD risk in 22,233 cases and 64,762 controls of European descent were obtained from the CARDIoGRAMplusC4D Consortium [35]. We identified 285 single-nucleotide polymorphisms (SNPs) associated with BMI as a genetic instrument with F statistics greater than 10 (explaining 2.89% of exposure variance), by extracting the effect sizes for SNP associated with BMI ( $P \le 5 \times 10^{-8}$ ) from summary statistics. As the extracted SNPs for BMI might be correlated with each other, we pruned the variants by linkage disequilibrium (LD) ( $r^2 < 0.01$ , clumping window = 10000 kbp). Then we tested whether these SNPs violate the exclusion restriction assumption. Firstly we plotted funnel plot (Figure 3) and found three SNPs were outliers. After removing them, the funnel plots were more symmetric. The Egger test revealed no significant effects of the mediators, HDL (P = 0.204), TG (P = 0.349) and the outcome CVD (P = 0.071). These results indicate the absence of directional pleiotropy. Details of the SNPs are listed in S1 Appendix. Firstly, we performed a single mediator analysis for the mediators (HDL and TG) via PSE-MR. Table 1 suggests TG and HDL are mediators in the causal pathway from BMI to CVD. Then we performed PSE-MR analysis with multiple mediators to test whether BMI has indirect effects on CVD risk through HDL and TG. Although a higher BMI increase the risk of CVD, no significant direct effect was obtained after adjusting for genetic associations with TG and HDL. Indirect effects through TG and HDL explained a large proportion of causal effect from BMI to CVD, and their total mediation proportion (MP) is 93.44%. In conclusion, three pathways exist from BMI to CVD: BMI→HDL→CVD (MP: 27.1% [17.1, 38.2]), BMI→TG→CVD (MP: 24.9% [16.3, 34.7]) and BMI→TG→HDL→CVD (MP: 23.7% [2.5, 49.3]). These results (Figure 4) are consistent with results from a pooled analysis of 97 prospective cohorts with 1.8 million participants [37] and previously described biological mechanisms [36, 38].

#### 4 Simulation

#### 4.1 Settings

280

281

282

283

284

285

286

287

288

289

290

291

292

- 293 To validate the utility of the PSE-MR method for estimating PSEs, we designed six scenarios:
- when Assumption III is satisfied (PSE-IVW) or violated (PSE-Egger) for settings with one
- 295 mediator (simulations A, B), multiple causally non-ordered (simulation C, D) and multiple
- 296 causally ordered mediators (simulation E, F).
- We generated data on 25 genetic variants, an exposure (X), mediators (M), and outcome
- 298 (Y) for 20,000 individuals. Briefly, we specified different values of the parameters  $\theta_D$  (the
- 299 direct effect of X on Y) and  $\theta_I$  (the indirect effect of X on M) to observe performances of

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

our methods. According to the specification of  $\theta_D$  and  $\theta_I$ , simulations from A to F included four settings: no direct effect, no indirect effect, a direct effect along with a directionally concordant indirect effect, and a direct effect and a directionally discordant indirect effect. For PSE-Egger, the data were simulated to consider the following three cases: Case (a): Balanced pleiotropy, InSIDE assumption satisfied; Case (b): Directional pleiotropy, InSIDE assumption satisfied: Case (c): Directional pleiotropy, InSIDE assumption not satisfied. We also performed additional simulations for sensitivity analyses, where bidirectional causal effects between the exposure and mediators, population homogeneity assumption is violated, the causal order is misspecified and one of the mediators is missing. In addition, we also consider the performance of PSE-MR when the exposure and outcome are time varying. We also find the optimal number of genetic variants when we consider multiple mediators. Details of the simulation are presented in S2 Appendix. We used the following metrics to evaluate performance of our methods: mean bias, standard errors (SE), mean square error (MSE), type I error rate for a null causal effect and empirical power to detect a non-null effect (i.e., the proportion of confidence intervals excluding zero). 4.2 Results We varied the sample size, the number of instrumental variables, and simulated four scenarios for different sets of parameter values. We found that causal estimates of direct and indirect

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

effects were unbiased with good Type I error properties. As the sample size increased, bias and standard errors decreased, while power improved. Higher power and lower bias were observed as the number of instrumental variables increased (see S2 Appendix, Section 1, 3 and 5). For two non-ordered mediators, PSE-IVW showed good performance of in standard MR when estimating the total, direct and indirect effects as well as three PSEs (Table 2). As the sample size and the number of genetic variants increased, the bias was smaller and the type I error was more stable at approximately 0.05 (see S2 Appendix, Section 3). The performance of PSE-MR based on IVW and MR-Egger with two non-ordered mediators in Case (a) and (b), are listed in eTables 9 to 12 (see S2 Appendix, section 4). In Case (a), we observed that the bias was close to zero and Type I error rates was around 0.05 in PSE-MR. PSE-Egger had less bias and more stable Type I error rates than IVW when directional pleiotropy existed in at least one pathway from G to Y (Case (b)). MR-Egger performed better than IVW in term of bias, even when the InSIDE assumption was not satisfied (Case (c)). When the pleiotropic effects through confounders (violating the InSIDE assumption) were 2.5 times larger than the direct pleiotropic effects (satisfying InSIDE), estimates from PSE-Egger were much less biased and rejection rates of the causal null hypothesis were much closer to the nominal 5% rate than those from PSE-IVW were. In all cases, PSE-Egger had smaller MSE and more stable Type I error rates (0.05) than PSE-IVW when the PSE was zero. Estimators of indirect effects based on product method had more stable Type I error rates (0.05) than those based on the difference method. Results for the two ordered multiple mediators were similar to those of two non-ordered mediators (Table 3 and eTables 17-24 in S2 Appendix, section 6). In addition, the magnitude of  $r_{qp}$  does not influence the performances of PSE-MR. Details are presented in eTable 15 (see S2 Appendix, section 5).

The estimation of direct effect is unbiased regardless of whether bidirectional causal effects between exposure and mediators exist, or the causal order is misspecified, though the estimation of PSEs is biased. Heterogeneous populations sometimes introduce bias of causal estimation for non-ordered and ordered mediators. Note that if we are missing upstream mediators (e.g.  $M_1$ ),  $M_1$  is the confounder of  $M_2$  and Y and it is affected by X (i.e. X-induced unmeasured confounder of  $M_2$  and Y). Thus the assumption of cross-world independence is violated. In addition, if we can obtain the information in each time points, PSE-MR can be applied into time varying exposure and mediators and it can also deal with the bi-directional relationship between exposure and mediators (see S1 Appendix, section 7-13). Performance of PSE-MR with different number of SNPs and mediators are listed in the eTable 41-42 and eFigure 9-10.

#### **5 Discussion**

In this paper, we develop a method PSE-MR to identify and estimate PSEs from an exposure on an outcome through the mediator(s) using MR when there are unmeasured confounders among the exposure, mediators and the outcome. We extend PSE-MR from a single mediator setting to the multiple mediator setting for both causally ordered and non-ordered mediators,

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

and outline the assumptions required to obtain causal effect. PSE-IVW can be used to explore the role of multiple mediators in the causal pathways between the exposure and outcome. The PSE-Egger can be viewed as a sensitivity analysis to provide robustness against both measured and unmeasured pleiotropy and to strengthen the evidence from the PSE-IVW analysis. PSE-MR can estimate the direct effects between the exposure and outcome and indirect effects through mediators when the sequential ignorability assumption [39] in mediation analyses is relaxed. We compared the assumptions of PSE-MR with traditional mediation analysis methods in Table 4. Our method requires other independent assumptions. While Assumptions | and | are testable, there is no accepted method to test for the Assumption | l. Several sensitivity analyses can be performed to examine this assumption, such as the E-value [28] and heterogeneity test. The validity of multiple mediators PSE-Egger and its ability to estimate consistent causal effects rely on the InSIDE assumption [21] being satisfied. When the direct genetic associations with the exposure are independent of the direct genetic associations with mediators and outcome, the InSIDE assumption is satisfied. Whereas the InSIDE assumption is plausible in some cases, it sometimes will not always be valid. For example, heterogeneous populations and misspecification of the multiple mediators would bias the mediation effect estimation. When  $\gamma_{kj}$  is not independent from each other or  $\gamma_{0i}$  is not independent with  $\gamma_{ki}$  for k=1,...,n (e.g. we are missing one of multiple mediators), the direct effect is downward-biased and the indirect effect is upward-biased.

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

According to our simulation, we find that PSE-IVW is more robust in estimating causal effect than PSE-Egger for heterogeneous populations and misspecified multiple mediators. However, PSE-Egger can be applied to test directional pleiotropy, and it can give less biased estimates when the InSIDE assumption is violated. For the multiple causally ordered mediator settings, PSE-MR can be widely used in time-varying exposure and mediators. Labrecque and Swanson (2019) [40] suggested that if the genetic associations of the exposure and mediators were time-varying, the lifetime effect estimate could be biased if we obtained the information of the exposure and mediators only at one time point. However, if we can obtain the information of the exposure and mediators at different time points, PSE-MR can provide unbiased estimates of the lifetime effects of the exposure and mediators on the outcome and other PSEs (see S2 Appendix, section 9). Thus PSE-MR can estimate each PSEs, including the causal relationships (which may potentially be bi-directional) in a non-experimental setting. In conclusion, we propose a method of causal mediation analysis with causally ordered and non-ordered mediators based on summarized genetic data and provides a new perspective for mediation analysis.

396 Reference

- 397 [1]. Lee, H., Herbert, R. D., & McAuley, J. H. (2019). Mediation Analysis. JAMA, 321(7),
- 398 697–698. https://doi.org/10.1001/jama.2018.21973
- 399 [2]. Kosuke, Imai, Luke, Keele, Teppei, & Yamamoto. (2010). Identification, inference and
- sensitivity analysis for causal mediation effects. Statistical Science.
- 401 [3]. Fulcher, I. R., Shi, X., & Tchetgen Tchetgen, E. J. (2019). Estimation of Natural Indirect
- 402 Effects Robust to Unmeasured Confounding and Mediator Measurement Error.
- 403 Epidemiology (Cambridge, Mass.), 30(6), 825–834.
- 404 https://doi.org/10.1097/EDE.0000000000001084
- 405 [4]. Mccandless, L. C., & Somers, J. M. (2017). Bayesian sensitivity analysis for
- 406 unmeasured confounding in causal mediation analysis. Statistical Methods in Medical
- 407 Research, 962280217729844.
- 408 [5], MacKinnon, D. P. (2000). Contrasts in multiple mediator models. Multivariate
- applications in substance use research: New methods for new questions, 141-160.
- 410 [6]. Avin, C., Shpitser, I., & Pearl, J. (2005). Identifiability of path-specific effects.
- 411 [7]. Imai, K., & Yamamoto, T. (2013). Identification and sensitivity analysis for multiple
- 412 causal mechanisms: Revisiting evidence from framing experiments. Political Analysis,
- 413 141-171.
- 414 [8]. Daniel, R. M., De Stavola, B. L., Cousens, S. N., & Vansteelandt, S. (2015). Causal
- mediation analysis with multiple mediators. Biometrics, 71(1), 1-14.

- 416 [9]. VanderWeele, T., & Vansteelandt, S. (2014). Mediation analysis with multiple mediators.
- 417 Epidemiologic methods, 2(1), 95-115.
- 418 [10]. Tchetgen, E. J. T., & Shpitser, I. (2012). Semiparametric theory for causal mediation
- analysis: efficiency bounds, multiple robustness, and sensitivity analysis. Annals of
- 420 statistics, 40(3), 1816.
- 421 [11]. Luo, P., & Geng, Z. (2016). Causal mediation analysis for survival outcome with
- 422 unobserved mediator–outcome confounders. Computational Statistics & Data Analysis,
- 423 93, 336-347.
- 424 [12]. VanderWeele, T. J., & Chiba, Y. (2014). Sensitivity analysis for direct and indirect
- effects in the presence of exposure-induced mediator-outcome confounders.
- 426 Epidemiology, biostatistics, and public health, 11(2).
- 427 [13]. Miles, C. H., Shpitser, I., Kanki, P., Meloni, S., & Tchetgen Tchetgen, E. J. (2020).
- On semiparametric estimation of a path-specific effect in the presence of
- mediator-outcome confounding. Biometrika, 107(1), 159-172.
- 430 [14]. Smith, L. H., & VanderWeele, T. J. (2019). Mediational E-values: approximate
- sensitivity analysis for unmeasured mediator-outcome confounding. Epidemiology,
- 432 30(6), 835-837.
- 433 [15]. Fulcher, I. R., Shi, X., & Tchetgen, E. J. T. (2019). Estimation of natural indirect effects robust
- to unmeasured confounding and mediator measurement error. *Epidemiology*, 30(6), 825-834.
- 435 [16]. Ding P, Vanderweele TJ. Sharp sensitivity bounds for mediation under unmeasured

- 436 mediator-outcome confounding. Biometrika. 2016;103(2):483-490.
- 437 doi:10.1093/biomet/asw012
- 438 [17]. Burgess, S., Small, D. S., & Thompson, S. G. (2017). A review of instrumental
- variable estimators for Mendelian randomization. Statistical methods in medical research,
- 440 26(5), 2333-2355.
- 441 [18]. Burgess, S., Butterworth, A., & Thompson, S. G. (2013). Mendelian randomization
- analysis with multiple genetic variants using summarized data. Genetic epidemiology,
- 443 37(7), 658-665.
- 144 [19]. Tikkanen, E., Gustafsson, S., Knowles, J. W., Perez, M., Burgess, S., & Ingelsson, E.
- 445 (2019). Body composition and atrial fibrillation: a Mendelian randomization study.
- European heart journal, 40(16), 1277-1282.
- 447 [20]. Burgess, S., & Thompson, S. G. (2015). Multivariable Mendelian randomization: the
- 448 use of pleiotropic genetic variants to estimate causal effects. American journal of
- epidemiology, 181(4), 251-260.
- 450 [21]. Rees, J. M., Wood, A. M., & Burgess, S. (2017). Extending the MR-Egger method
- for multivariable Mendelian randomization to correct for both measured and unmeasured
- pleiotropy. Statistics in medicine, 36(29), 4705-4718.
- 453 [22]. Burgess, S., Thompson, D. J., Rees, J. M., Day, F. R., Perry, J. R., & Ong, K. K.
- 454 (2017). Dissecting causal pathways using Mendelian randomization with summarized
- genetic data: application to age at menarche and risk of breast cancer. Genetics, 207(2),

- 456 481-487.
- 457 [23]. Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with
- invalid instruments: effect estimation and bias detection through Egger regression.
- International journal of epidemiology, 44(2), 512-525.
- 460 [24]. Taguri, M., Featherstone, J., & Cheng, J. (2018). Causal mediation analysis with
- multiple causally non-ordered mediators. Statistical methods in medical research, 27(1),
- 462 3-19.
- 463 [25]. Angrist, J. D., & Krueger, A. B. (1995). Split-sample instrumental variables
- estimates of the return to schooling. Journal of Business & Economic Statistics, 13(2),
- 465 225-235.
- 466 [26]. Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S. V., & Klungel, O. H. (2006).
- 467 Instrumental variables: application and limitations. Epidemiology, 260-267.
- 468 [27]. Staiger, D., & Stock, J. H. (1994). Instrumental variables regression with weak
- instruments (No. t0151). National Bureau of Economic Research.
- 470 [28]. Swanson, S. A., & VanderWeele, T. J. (2020). E-Values for Mendelian
- 471 Randomization. Epidemiology, 31(3), e23-e24.
- 472 [29]. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., ... &
- AlMazroa, M. A. (2012). Global and regional mortality from 235 causes of death for 20
- age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease
- 475 Study 2010. The lancet, 380(9859), 2095-2128.

- 476 [30]. Prospective Studies Collaboration. (2009). Body-mass index and cause-specific
- 477 mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet,
- 478 373(9669), 1083-1096.
- 479 [31]. Van Gaal, L. F., Mertens, I. L., & Christophe, E. (2006). Mechanisms linking obesity
- with cardiovascular disease. Nature, 444(7121), 875-880.
- 481 [32]. Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel,
- 482 R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect
- 483 of weight loss: an update of the 1997 American Heart Association Scientific Statement
- on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition,
- Physical Activity, and Metabolism. Circulation, 113(6), 898-918.
- 486 [33]. Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell,
- 487 J., ... & Yang, J. (2019). Meta-analysis of genome-wide association studies for body fat
- distribution in 694 649 individuals of European ancestry. Human molecular genetics,
- 489 28(1), 166-174.
- 490 [34]. Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., Kanoni,
- S., ... & Beckmann, J. S. (2013). Discovery and refinement of loci associated with lipid
- 492 levels. Nature genetics, 45(11), 1274.
- 493 [35]. Schunkert, H., König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., ...
- 494 & Absher, D. (2011). Large-scale association analysis identifies 13 new susceptibility
- loci for coronary artery disease. Nature genetics, 43(4), 333-338.

- 496 [36]. Lusis, A. J., Attie, A. D., & Reue, K. (2008). Metabolic syndrome: from
- 497 epidemiology to systems biology. Nature Reviews Genetics, 9(11), 819-830.
- 498 [37]. Lu, Y., Hajifathalian, K., Ezzati, M., Woodward, M., Rimm, E. B., & Danaei, G.
- 499 (2013). Metabolic mediators of the effects of body-mass index, overweight, and obesity
- on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with
- 1. 8 million participants. Lancet (London, England), 383(9921), 970-983.
- 502 [38]. de Freitas, E. V., Brandão, A. A., Pozzan, R., Magalhães, M. E., Fonseca, F., Pizzi,
- 503 O., ... & Brandão, A. P. (2011). Importance of high-density lipoprotein-cholesterol
- 504 (HDL-C) levels to the incidence of cardiovascular disease (CVD) in the elderly. Archives
- of gerontology and geriatrics, 52(2), 217-222.
- 506 [39]. Tchetgen, E. J. T., & Shpitser, I. (2012). Semiparametric theory for causal mediation
- analysis: efficiency bounds, multiple robustness, and sensitivity analysis. Annals of
- statistics, 40(3), 1816.
- 509 [40]. Labrecque, J. A., & Swanson, S. A. (2020). Commentary: Mendelian randomization
- with multiple exposures: the importance of thinking about time. International journal of
- 511 epidemiology, 49(4), 1158-1162.
- 512 [41]. Didelez, V., & Sheehan, N. (2007). Mendelian randomization as an instrumental
- variable approach to causal inference. Statistical methods in medical research, 16(4),
- 514 309-330.
- 515 [42]. Burgess, S., & Thompson, S. G. (2017). Interpreting findings from Mendelian

- randomization using the MR-Egger method. European journal of epidemiology, 32(5),
- 517 377-389.
- 518 [43]. Labrecque, J. A., & Swanson, S. A. (2020). Commentary: Mendelian randomization
- with multiple exposures: the importance of thinking about time. International journal of
- 520 epidemiology, 49(4), 1158-1162.
- 521 [44]. VanderWeele, T. J., Vansteelandt, S., & Robins, J. M. (2014). Effect decomposition
- in the presence of an exposure-induced mediator-outcome confounder. Epidemiology
- 523 (Cambridge, Mass.), 25(2), 300.
- 524 [45]. Mittinty, M. N., Lynch, J. W., Forbes, A. B., & Gurrin, L. C. (2019). Effect
- decomposition through multiple causally nonordered mediators in the presence of
- exposure induced mediator outcome confounding. Statistics in medicine, 38(26),
- 527 5085-5102.
- 528 [46]. VanderWeele, T. J., & Vansteelandt, S. (2009). Conceptual issues concerning
- mediation, interventions and composition. Statistics and its Interface, 2(4), 457-468.
- 530 [47]. Loh, W. W., Moerkerke, B., Loeys, T., & Vansteelandt, S. (2020). Non-linear
- mediation analysis with high-dimensional mediators whose causal structure is unknown.
- 532 arXiv preprint arXiv:2001.07147...
- 533 [48]. Valeri, L., & VanderWeele, T. J. (2013). Mediation analysis allowing for
- exposure–mediator interactions and causal interpretation: theoretical assumptions and
- 535 implementation with SAS and SPSS macros. Psychological methods, 18(2), 137.

- 536 [49]. VanderWeele, T. J. (2014). A unification of mediation and interaction: a four-way
- decomposition. Epidemiology (Cambridge, Mass.), 25(5), 749.
- 538 [50]. VanderWeele, T. J., & Tchetgen, E. J. T. (2017). Mediation analysis with time
- varying exposures and mediators. Journal of the Royal Statistical Society. Series B,
- 540 Statistical Methodology, 79(3), 917.
- 541 [51]. Tchetgen, E. J. T., & VanderWeele, T. J. (2014). On identification of natural direct
- effects when a confounder of the mediator is directly affected by exposure. Epidemiology
- 543 (Cambridge, Mass.), 25(2), 282.
- 544 [52]. Vansteelandt, S., Linder, M., Vandenberghe, S., Steen, J., & Madsen, J. (2019).
- Mediation analysis of time-to-event endpoints accounting for repeatedly measured
- mediators subject to time-varying confounding. Statistics in medicine, 38(24),
- 547 4828-4840.

- 548 [53]. Zheng, W., & van der Laan, M. (2017). Longitudinal mediation analysis with
- 549 time-varying mediators and exposures, with application to survival outcomes. Journal of
- causal inference, 5(2).

| IVW                |  | MR-Egger   |   |   |
|--------------------|--|--|---|---|
| OR[95% CI]         | Power  | OR[95% CI]   | Power   |   |
| 1.216[1.034,1.431] | 1  | 1.772[1.208,2.600]   | 1   |   |
| 1.013[0.850,1.208] | -  | 1.391[0.945,2.048]   | -   |   |
| 1.054[1.034,1.101] | 0.97   | 1.097[1.040,1.125]   | 1   |   |
| 1.050[1.033,1.096] | 0.97   | 1.068[1.027,1.137]   | 1   |   |
| 1.047[1.005.1.101] | 0.7  | 1.052[1.000.1.125]   | 0.8   |   |
|                    |  |  |   |   |
|                    |  |  |   |   |
|                    | 1.216[1.034,1.431]<br>1.013[0.850,1.208]<br>1.054[1.034,1.101]<br>1.050[1.033,1.096]<br>1.047[1.005,1.101] | 1.216[1.034,1.431] 1 1.013[0.850,1.208] - 1.054[1.034,1.101] 0.97 1.050[1.033,1.096] 0.97 1.047[1.005,1.101] 0.7 | 1.216[1.034,1.431]       1       1.772[1.208,2.600]         1.013[0.850,1.208]       -       1.391[0.945,2.048]         1.054[1.034,1.101]       0.97       1.097[1.040,1.125]         1.050[1.033,1.096]       0.97       1.068[1.027,1.137]         1.047[1.005,1.101]       0.7       1.052[1.000,1.125] | 1.216[1.034,1.431]     1     1.772[1.208,2.600]     1       1.013[0.850,1.208]     -     1.391[0.945,2.048]     -       1.054[1.034,1.101]     0.97     1.097[1.040,1.125]     1       1.050[1.033,1.096]     0.97     1.068[1.027,1.137]     1 |

**Table 2**. Simulation of PSE-IVW with two non-ordered mediators in standard MR

**Table 3.** Simulation of PSE-IVW with two ordered mediators in standard MR

| 1.3 0.8 0.5 0 0.3 0.2 1.31 0.75 0.56 0.56 0.02 0.29 0.25 0.00 0.00 0.01 0.01 0.00 0.02 0.02 1.00 1.00   |      |         | Tr   | ue    |         |         |       |       | E     | Estimate | s     |       |      |      |      |      | MSE  |      |      |      |      | medRxiv prowe           | r/Type I | error |      |     |
|---|------|---------|------|-------|---------|---------|-------|-------|-------|----------|-------|-------|------|------|------|------|------|------|------|------|------|-------------------------|----------|-------|------|-----|
| 0.8   | TE   | DE      | IE   | IE1   | IE2     | IE3     | TE    | DE    | IE_d  | IE_p     | IE1   | IE2   | IE3  | TE   | DE   | IE_d | IE_p | IE1  | IE2  | IE3  | TE   | DE SE_d                 | IE_p     | IE1   | IE2  | I   |
| 1.2 0.8 0.4 0.5 -0.3 0.2 1.20 0.75 0.45 0.45 0.45 0.54 -0.26 0.16 0.01 0.00 0.01 0.01 0.01 0.01 0.0   | 1.8  | 0.8     | 1    | 0.5   | 0.3     | 0.2     | 1.81  | 0.75  | 1.06  | 1.06     | 0.52  | 0.28  | 0.25 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 1.00 | 1.00 0 0 0 0 0          | 1.00     | 0.97  | 0.64 | 0.  |
| 0.2   | 0.8  | 0.8     | 0    | -0.5  | 0.3     | 0.2     | 0.81  | 0.75  | 0.05  | 0.05     | -0.48 | 0.29  | 0.24 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 1.00 | 1.00 0.01               | 0.00     | 1.00  | 0.70 | 0.  |
| 0.2 -0.8 1 0.5 0.3 0.2 0.21 -0.84 1.05 1.06 0.52 0.29 0.25 0.01 0.00 0.01 0.01 0.00 0.02 0.02 0.01 1.00 1.00  | 1.2  | 0.8     | 0.4  | 0.5   | -0.3    | 0.2     | 1.20  | 0.75  | 0.45  | 0.45     | 0.54  | -0.26 | 0.16 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 1.00 | <del></del>             | 0.72     | 1.00  | 0.69 | 0.  |
| -1.8  -0.8  -1  -0.5  -0.3  -0.2  -1.80  -0.85  -0.96  -0.96  -0.96  -0.48  -0.25  -0.23  0.01  0.00  0.01  0.01  0.00  0.02  0.01  1.00  1.00  1.00  1.00  1.00  0.66  0.01  1.00  1.00  1.00  0.00  0.00  1.00  1.00  0.00  0.00  0.00  1.00  0.00  | 0.2  | 0.8     | -0.6 | -0.5  | -0.3    | 0.2     | 0.20  | 0.76  | -0.56 | -0.56    | -0.46 | -0.25 | 0.16 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.97 | 1.00 1.00               | 1.00     | 1.00  | 0.68 | 0.  |
| 1 0 1 0.5 0.3 0.2 1.01 -0.05 1.05 1.05 0.52 0.29 0.25 0.01 0.00 0.01 0.01 0.00 0.02 0.02 1.00 0.00 0  | 0.2  | -0.8    | 1    | 0.5   | 0.3     | 0.2     | 0.21  | -0.84 | 1.05  | 1.06     | 0.52  |       | 0.25 | 0.01 |      | 0.01 | 0.01 | 0.00 |      | 0.02 | 0.71 | 77.                     | 1.00     | 1.00  | 0.67 | 0.  |
| 1.3 0.8 0.5 0 0.3 0.2 1.31 0.75 0.56 0.56 0.02 0.29 0.25 0.00 0.00 0.01 0.01 0.00 0.02 0.02 1.00 1.00   | -1.8 | -0.8    | -1   |       |         |         | -1.80 |       |       |          |       |       |      | 0.01 |      | 0.01 | 0.01 | 0.00 |      | 0.01 | 1.00 | ~ ~ ~                   |          | 1.00  | 0.66 | 0.  |
| 1.5 0.8 0.7 0.5 0 0.2 1.51 0.77 0.74 0.74 0.74 0.52 -0.03 0.25 0.01 0.00 0.01 0.01 0.00 0.02 0.02 1.00 1.60 1.60 1.60 1.60 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.07 0.09 0.09   | 1    |         | 1    | 0.5   |         |         |       |       |       |          |       |       |      |      |      |      |      |      |      |      |      | ~ ~ N                   |          |       |      | 0.  |
| 1 0.8 0.2 0 0 0 0.2 1.01 0.77 0.24 0.24 0.02 -0.03 0.25 0.00 0.00 0.01 0.01 0.00 0.02 0.02 1.00 1.00  |      |         |      |       |         |         |       |       |       |          |       |       |      |      |      |      |      |      |      |      |      | <del>2</del> 0 -        |          |       |      |     |
| 0 -1 1 0.5 0.3 0.2 0.01 -1.05 1.06 1.06 0.52 0.29 0.25 0.01 0.00 0.01 0.01 0.00 0.02 0.02 0.05 1.00 1.00 1.00 0.69 0.  TE: total effect; DE: direct effect; IE: indirect effect; IE: $X \rightarrow M_1 \rightarrow Y$ ; IE2: $X \rightarrow M_2 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE_d: indirect effect calculated by difference method; IE_p: indirect effect.  | 1.5  |         |      |       |         |         |       |       |       |          |       |       |      |      |      |      |      |      |      |      |      | <u> </u>                |          |       |      |     |
| TE: total effect; DE: direct effect; IE: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE2: $X \rightarrow M_2 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE_d: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE_d: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE4: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE4: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE4: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE3: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE4: indirect effect calculated by a difference method; IE_p: indirect effect; IE1: $X \rightarrow M_1 \rightarrow Y$ ; IE4: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; IE5: $X \rightarrow M_1 \rightarrow M_2 \rightarrow Y$ ; | 1    | 0.8     | 0.2  | 0     |         |         |       |       |       |          |       |       |      |      |      |      |      |      |      |      |      | <del>~ 5 <u>+</u></del> |          |       |      | 0.  |
|   | TE:  | total e |      | DE: d | irect 6 | effect; |       |       |       |          |       |       |      |      |      |      |      |      |      |      |      | ted by differ           |          |       |      | inc |

**Table 4.** Comparison of the assumption in PSE-MR and typical causal mediation analysis

| Methods   | PSE-MR  | Typical causal mediation analysis                            | Solution for value assumptions           |
|-----------|---|--|--|
|           | (1) Consistency assumption: $M(x)=M$ and $Y(x)=M$ | $f(x)=Y \text{ if } X=x; \ Y(x,m)=Y \text{ if } X=x, \ M=m.$ | not c                                    |
|           | (2) Composition assumption: $Y(x) = Y(x, M(x))$   | ) if <i>X</i> = <i>x</i> .                                   | oertifie                                 |
| Common    | (3) A cross-world independence assumption:        | $Y(x,m) \perp M(x^*) \mid C \text{ for all } (x, x^*, m).$   | [10] [44] [45 👸 1]                       |
|           | (4) There is no additive interaction of the ex    | posure and the mediators on the outcome ( <i>Y</i> ).        | [10] [46] [48][29]                       |
|           | (5) Linearity.                                    |  | [10] [47] may 20 21                      |
|           | (1) The IV $G_j$ is associated with the           | (1) No-unmeasured confounders of the X-Y                     | [10] [15] 2021.01.                       |
|           | exposure <i>X</i> but independent of all the      | relation, that is, $Y(x,m) \perp X \mid C$ for all $(x,m)$ . | 01.07<br>authorable u                    |
|           | unmeasured confounders.                           |  | 21249.<br>or/fund<br>nder a              |
|           | (2) The Exclusion restriction assumption          | (2) No-unmeasured confounders of the <i>M-Y</i>              | [10] [11] [12] [3] [14] [15][16]         |
|           | or the InSIDE assumption.                         | relation, that is, $Y(x,m) \perp M(x) \mid X = x, C$         | is vers<br>o has<br>Y-NC-                |
|           |   | for all $(x,m)$ .  | version pos<br>has granted<br>-NC-ND 4.0 |
| Different | (3) There is no additive interaction of the       | (3) No-unmeasured confounders of the <i>X-M</i>              | [10] [15] Regard                         |
|           | exposure or the mediators and confounders         | relation, that is, $M(x) \perp X \mid C$ for all $x$ .       | anuar<br>Rxiv a<br>Pationa               |
|           | on the mediator $(M)$ and the outcome $(Y)$ .     |  | / 8, 202<br>license                      |
|           | (4) Data for exposure, mediators and              | (4) Data for exposure, mediators and outcome                 | Φ ₹ . →                                  |
|           | outcome can from different datasets with          | must from the same dataset.                                  | he copisplay                             |
|           | homogeneous population.                           |  | The copyright odisplay the pre           |
|           |   | (5) Exposure, mediators and confounders not                  |  |
|           |   | vary with time.  | in pe                                    |

Figure legends

**Figure 1.** Three types of settings with two mediators,  $M_1$  and  $M_2$  are shown in (A) where  $M_1$ 

is independent of  $M_2$ ; (B) where  $M_1$  is related to  $M_2$ , but not causally; and (C) where  $M_1$  is

causally related to  $M_2$  (causally-ordered mediators). Graphical diagrams for PSE-MR are

given in settings with one mediator (D), two non-ordered mediators (E), and two ordered

mediators (F). X: the exposure,  $M_1$  and  $M_2$ : two mediators, Y: outcome, G: instrumental

variables (genetic variants).

**Figure 2.** Graphical diagrams of relationships between the exposure (X), causally

non-ordered mediators  $(M_1, ..., M_n)$ , outcome (Y), and instrumental variables (G), which

omits the confounders among X, M and Y, are shown as analyzed with (A) PSE-IVW and (B)

PSE-Egger. Graphical diagrams of relationships between exposure (X), causally ordered

mediators  $(M_1, ..., M_n)$ , outcome (Y), and instrumental variables (G), which omits the

confounders (U) among  $X, M_1, ..., M_n$  and Y are shown, as analyzed with (C) PSE-IVW and

(D) PSE-Egger.

Figure 3. Funnel plots before (A-D) and after (E-H) removing outliers.

Figure 4. Diagrams of the causal pathway from BMI to CVD. BMI, body mass index; CVD,


34


cardiovascular disease; TG, triacylglycerol; HDL, high-density lipoprotein.


**Supplementary Digital Content** 


**S1 Appendix.** Supplemental methods.

**S2 Appendix.** Supplemental simulations.









BMI→HDL→CVD

OR: 1.054[1.034,1.101]

MP: 27.1% [17.1, 38.2])

 $BMI \rightarrow TG \rightarrow CVD$ 

OR: 1.050[1.033,1.096]

MP: 24.9% [16.3, 34.7]

 $BMI \rightarrow TG \rightarrow HDL \rightarrow CVD$ 

OR: 1.047[1.005,1.101]

MP: 23.7% [2.5, 49.3]